PURPOSE: This study aims to demonstrate that 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) positron emission tomography (PET) is a promising modality for noninvasively monitoring the therapeutic efficacy of Doxisome(®) in a subcutaneous hepatoma mouse model. PROCEDURES: Male BALB/c nu/nu mice were inoculated with HepG2 hepatoma xenograft in the right flank. Doxisome(®) (5 mg/kg, three times a week for 2 weeks) was intravenously administrated for treatment. (18)F-FLT-microPET, biodistribution studies, and immunohistochemistry of Ki-67 were performed. RESULTS: A significant difference (p < 0.05) in tumor volume was observed on day 5 between treated and control groups. The tumor-to-muscle ratio derived from (18)F-FLT-PET and (123)I-ICdR-microSPECT images of Doxisome(®)-treated mice dropped from 12.55 ± 0.76 to 3.81 ± 0.31 and from 2.48 ± 0.42 to 1.59 ± 0.08 after a three-dose treatment, respectively, while that of the control group remained steady. The retarded proliferation rate of treated xenograft was confirmed by Ki-67 immunohistochemistry staining. CONCLUSIONS: This study clearly demonstrated that Doxisome(®) is an effective anti-cancer drug against the growth of HepG2 hepatoma and that (18)F-FLT-PET could provide early information of tumor response during treatment.
PURPOSE: This study aims to demonstrate that 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) positron emission tomography (PET) is a promising modality for noninvasively monitoring the therapeutic efficacy of Doxisome(®) in a subcutaneous hepatomamouse model. PROCEDURES: Male BALB/c nu/nu mice were inoculated with HepG2 hepatoma xenograft in the right flank. Doxisome(®) (5 mg/kg, three times a week for 2 weeks) was intravenously administrated for treatment. (18)F-FLT-microPET, biodistribution studies, and immunohistochemistry of Ki-67 were performed. RESULTS: A significant difference (p < 0.05) in tumor volume was observed on day 5 between treated and control groups. The tumor-to-muscle ratio derived from (18)F-FLT-PET and (123)I-ICdR-microSPECT images of Doxisome(®)-treated mice dropped from 12.55 ± 0.76 to 3.81 ± 0.31 and from 2.48 ± 0.42 to 1.59 ± 0.08 after a three-dose treatment, respectively, while that of the control group remained steady. The retarded proliferation rate of treated xenograft was confirmed by Ki-67 immunohistochemistry staining. CONCLUSIONS: This study clearly demonstrated that Doxisome(®) is an effective anti-cancer drug against the growth of HepG2 hepatoma and that (18)F-FLT-PET could provide early information of tumor response during treatment.
Authors: Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga Journal: Eur J Nucl Med Mol Imaging Date: 2004-12 Impact factor: 9.236
Authors: David S Alberts; Franco M Muggia; James Carmichael; Eric P Winer; Mohammad Jahanzeb; Alan P Venook; Keith M Skubitz; Edgardo Rivera; Joseph A Sparano; Nicholas J DiBella; Simon J Stewart; John J Kavanagh; Alberto A Gabizon Journal: Semin Oncol Date: 2004-12 Impact factor: 4.929
Authors: Andreas K Buck; Gisela Halter; Holger Schirrmeister; Jörg Kotzerke; Imke Wurziger; Gerhard Glatting; Torsten Mattfeldt; Bernd Neumaier; Sven N Reske; Martin Hetzel Journal: J Nucl Med Date: 2003-09 Impact factor: 10.057
Authors: Bishnuhari Paudyal; Kaijun Zhang; Chang-Po Chen; Matthew E Wampole; Neil Mehta; Edith P Mitchell; Brian D Gray; Jeffrey A Mattis; Koon Y Pak; Mathew L Thakur; Eric Wickstrom Journal: Nucl Med Biol Date: 2013-09-24 Impact factor: 2.408